Human Genome Sciences (HGSI) Calls It; Says July 16th Deadline for Bids (GSK)

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS. In this regard, HGS yesterday sent a letter to GlaxoSmithKline (NYSE: GSK) once again inviting GSK to participate in the ongoing process according to the same procedures previously established and to provide, by no later than July 16, 2012, GSK’s final bid terms, including a response to a draft agreement which will be provided to all interested bidders. The letter specifically noted that the HGS Board of Directors has previously rejected $13.00 per share as inadequate.

HGS is committed to completing its exploration of strategic alternatives in a manner that ensures that HGS stockholders have the benefit of a complete and fair process and welcomes GSK to fully participate in such process.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Holcim to acquire Fermacell from James Hardie for EUR 840M
• Hertz Global amends voting agreement with CK Amarillo after lawsuit
• Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands